WG
ACRS icon

Winton Group’s Aclaris Therapeutics ACRS Stock Holding History

Winton Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-47,559
Closed -$122K – 1304
2020
Q3 		$122K Buy
47,559
+2,382
+5% +$5.33K ﹤0.01% 1387
2020
Q2 		$73K Sell
45,177
-70,662
-61% -$94.7K ﹤0.01% 1411
2020
Q1 		$120K Sell
115,839
-85,978
-43% -$117K ﹤0.01% 1307
2019
Q4 		$381K Sell
201,817
-8,640
-4% -$14.3K 0.01% 1311
2019
Q3 		$227K Buy
+210,457
New +$299K ﹤0.01% 1359

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Winton Group's ACRS Position: Q4 2020 in Review

Winton Group sold out of Aclaris Therapeutics (ACRS) in Q4 2020, closing a stake of 47,559 shares — an estimated $122K sold.

Winton Group first reported a position in ACRS in Q3 2019 and held it in 5 quarters. The position peaked at $381K in Q4 2019. 82 funds tracked by Wall St. Rank hold ACRS as of Q4 2020.

  • Winton Group reported no remaining Aclaris Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 47,559 Aclaris Therapeutics shares in Q4 2020, an estimated $122K.
  • Winton Group first reported a position in Aclaris Therapeutics in Q3 2019 and held it in 5 quarters.
  • Winton Group's Aclaris Therapeutics position peaked at $381K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.